Clinical Trials Browser

Interventional × urelumab × Clear all

NCT02845323 2026-04-06

Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder

Phase 2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT02451982 2025-12-03

Platform Study of Neoadjuvant and Adjuvant Immunotherapy for Patients With Resectable Adenocarcinoma of the Pancreas

Phase 2 Active not recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT02652455 2025-08-19

Combining PD-1 Blockade, CD137 Agonism and Adoptive Cell Therapy for Metastatic Melanoma

Phase EARLY_PHASE1 Completed

Melanoma, Skin Neoplasms

NCT02658981 2023-10-06

Anti-LAG-3 Alone & in Combination w/ Nivolumab Treating Patients w/ Recurrent GBM (Anti-CD137 Arm Closed 10/16/18)

Phase 1 Completed

Brain Neoplasms, Glioblastoma, Gliosarcoma

NCT03431948 2023-02-16

C4-MOSART

Phase 1 Completed

Neoplasms

NCT02253992 2020-10-05

An Investigational Immuno-therapy Study to Determine the Safety of Urelumab Given in Combination With Nivolumab in Solid Tumors and B-cell Non-Hodgkin's Lymphoma

Phase 1/2 Terminated

232 enrolled 17 charts

LymphoidOther solid neoplasm

Advanced Solid Tumors

NCT02534506 2020-05-18

Study of Urelumab in Subjects With Advanced and/or Metastatic Malignant Tumors

Phase 1 Completed

Neoplasms

NCT03792724 2019-01-03

INTRUST

Phase 1/2 Unknown

Neoplasms

NCT02252263 2017-11-01

A Phase I Open Label Study of the Safety and Tolerability of Elotuzumab (BMS-901608) Administered in Combination With Either Lirilumab (BMS-986015) or Urelumab (BMS-663513) in Subjects With Multiple Myeloma

Phase 1 Completed

Multiple Myeloma

NCT01471210 2017-04-19

Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma

Phase 1 Completed

Lymphoma, B-Cell

NCT02110082 2017-04-19

Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer

Phase 1 Completed

GastrointestinalHead & Neck

Head and Neck Neoplasms, Colorectal Neoplasms

NCT01775631 2017-03-31

Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma

Phase 1 Completed

B-Cell Malignancies

NCT02420938 2016-12-06

Urelumab (CD137 mAb) With Rituximab for Relapsed, Refractory or High-risk Untreated Chronic Lymphocytic Leukemia (CLL) Patients

Phase 2 Withdrawn

LymphoidOther hematologic neoplasm

Leukemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell

NCT00309023 2015-10-12

Study of BMS-663513 in Patients With Advanced Cancer

Phase 1/2 Terminated

Neoplasms

NCT00612664 2015-10-12

Phase II, 2nd Line Melanoma - RAND Monotherapy

Phase 2 Completed

Melanoma

NCT00803374 2011-11-21

Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma

Phase 1 Withdrawn

Melanoma

NCT00351325 2009-09-04

A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies

Phase 1 Terminated

Advanced Solid Malignancies

NCT00461110 2009-09-04

A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)

Phase 1 Terminated

Carcinoma, Non-Small-Cell Lung